Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
IPO Year: 2020
Exchange: NASDAQ
Website: https://www.bioratherapeutics.com
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)
SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman, MD, as Chief Medical Officer. Dr. Kelman has a proven track record of leading global biopharmaceutical development, clinical trials, and regulatory strategies. "Dr. Kelman is an outstanding addition to our team as we progress our programs into later stages of development and prepare to enter the clinic with the BT-600 program, which is designed to deliver our unique formulation of tofacitinib to the colon using our proprietary GItrac™ technology," said Adi Mohanty, Chief Executive Officer of Bio
SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutics, announced today the appointment of Dr. Bruce Sands as board chair of its Clinical Advisory Board for Inflammatory Bowel Disease (IBD), which also includes leading IBD researchers Dr. Geert D'Haens, Dr. Brian Feagan, and Dr. Séverine Vermeire. The clinical advisory board provides strategic guidance on clinical development of Biora's Targeted Therapeutics pipeline. "Targeted drug delivery to the large intestine has the potential to enable new therapeutic approaches, including combination therapy, for IBD patients," said Dr. Bruce Sands. "I'm pleased to
SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced it has been awarded ISO 13485:2016 certification by TÜV SÜD America, demonstrating the company's commitment to compliance with the most rigorous global regulatory and quality standards. "We are proud of the robust systems our team has built, ensuring stringent control over development and manufacturing processes," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "This certification demonstrates our ongoing ability to meet exacting regulatory requirements as we continue to achieve clinical and developmental milestones
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced that the company has been granted an extension to regain compliance with Nasdaq listing requirements. "We shared with Nasdaq the upcoming company catalysts that we believe will drive significant value for shareholders, and we are pleased with their decision to grant us an extension to regain compliance," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "We look forward to continuing to achieve milestones in the development of our innovative NaviCap™ and BioJet™ therapeutics platforms." The Nasdaq Hearings Panel granted
SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate in the H.C. Wainwright 26th Annual Global Investment Conference, September 9–11, 2024. H.C. Wainwright 26th Annual Global Investment Conference, New York, NYCompany presentation and 1x1 investor meetingsDate:Wednesday, September 11, 2024Time:2:00 PM Eastern timeLive Webcast:https://journey.ct.events/view/1cda5986-f016-485c-9afa-6c3bcfc9d834 A replay will also be available on Biora's website following the conference. About Biora TherapeuticsBiora Therapeutics is a clinical-stage biotech de
Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan Company secures up to $16M funding from existing investors supported by BT-600 results and progress toward BioJet™ partnership Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. "Research shows that ulcerative colitis patients with higher drug exposur
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced the signing of financing agreements with its existing convertible notes holders. "We appreciate the continued commitment of our existing noteholders, who have agreed to an additional investment in Biora that we expect will fund us to important milestones, including anticipated partnering with large pharma," said Eric d'Esparbes, Chief Financial Officer of Biora Therapeutics. "Active pharma collaborator interest in our BioJet™ platform, and recent promising clinical trial results from our NaviCap™ platform, are drivers for this commitmen
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the second quarter ended June 30, 2024. Company management will host a webcast and conference call on Monday, August 12, 2024, after the close of financial markets. Conference Call and Webcast InformationDate:Monday, August 12, 2024Time:4:30 PM Eastern time / 1:30 PM Pacific timeConference Call:Domestic 1-877-423-9813 International 1-201-689-8573 Conference ID 13747616Call me for instant telephone accessLive Webcast:https://investors.bioratherapeutics.com/events-presenta
SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate in the Canaccord Genuity 44th Annual Growth Conference, August 13–15, 2024. Canaccord Genuity 44th Annual Growth Conference, Boston, MACompany presentation and 1x1 investor meetings Date: Tuesday, August 13, 2024 Time: 2:30 PM Eastern time Live Webcast:https://wsw.com/webcast/canaccord98/bior/2458676 A replay will also be available on Biora's website following the conference. About Biora TherapeuticsBiora Therapeutics is a clinical-stage biotech developing two smart
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data modeling suggests tofacitinib tissue concentrations greater than IC90 through at least 16 hours after dosing SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, presented supplemental data from the Phase 1 trial of BT-600 during the company's virtual KOL event on Wednesday, July 17, 2024. BT-600, an orally administered drug-device combination, is in development for the treatment of patients with ulcerative colitis (UC). BT-600 leverages Biora's ingest
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday, July 17, 2024. The event will feature Bruce Sands, MD, MS (Icahn School of Medicine at Mount Sinai) and Brian Feagan, MD, FRCPC (Schulich School of Medicine & Dentistry at the University of Western Ontario), who will discuss the unmet need and current treatment landscape for patients with ulcerative colitis (UC), as well as the value of colonic drug delivery for improving efficacy. Biora leadership will highlight key results from the Phase 1 clinical trial of BT-600, an ora
Drug-device combination leverages Biora's NaviCap™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform's ability to deliver therapeutics directly to the colon Drug absorption in colonic tissue extended to distal colon, suggesting pan-colonic delivery Company to host virtual event with key opinion leaders on July 17 SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today shared positive topline resul
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
EFFECT - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
PRE 14A - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
S-3 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
424B5 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
424B5 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
424B5 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
424B5 - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13G - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13G/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
SC 13G - BIORA THERAPEUTICS, INC. (0001580063) (Subject)
Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan Company secures up to $16M funding from existing investors supported by BT-600 results and progress toward BioJet™ partnership Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. "Research shows that ulcerative colitis patients with higher drug exposur
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the second quarter ended June 30, 2024. Company management will host a webcast and conference call on Monday, August 12, 2024, after the close of financial markets. Conference Call and Webcast InformationDate:Monday, August 12, 2024Time:4:30 PM Eastern time / 1:30 PM Pacific timeConference Call:Domestic 1-877-423-9813 International 1-201-689-8573 Conference ID 13747616Call me for instant telephone accessLive Webcast:https://investors.bioratherapeutics.com/events-presenta
Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Clinical data on device function of the NaviCap™ platform to be presented at DDW on May 19 Partnering process for the BioJet oral delivery platform is progressing well Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. "We were gratified to see the excellent int
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the first quarter ended March 31, 2024. The company's management will host a webcast and conference call on Wednesday, May 15, 2024, after the close of financial markets. Conference Call and Webcast Information Date: Wednesday, May 15, 2024 Time: 4:30 PM Eastern time / 1:30 PM Pacific time Conference Call: Domestic 1-877-423-9813 International 1-201-689-8573 Conference ID 13746163 Call me for instant telephone access Live Webcast: https://investors.bior
All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower drug levels in blood Remainder of BT-600 clinical trial progressing well and on schedule Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2023. "We are thrilled by t
SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the fourth quarter and full year ended December 31, 2023. The company's management will host a webcast and conference call on Tuesday, March 26, 2024, after the close of financial markets. Conference Call and Webcast InformationDate:Tuesday, March 26, 2024Time:4:30 PM Eastern time / 1:30 PM Pacific timeConference Call:Domestic 1-877-423-9813 International 1-201-689-8573 Conference ID 13744533 Call me for instant telephone accessLive Webcast:https://investors.bio
NaviCap™ Targeted Oral Delivery platform advancing toward initiation of phase 1 clinical trial by year end Pharma collaborations accelerate for the BioJet™ Systemic Oral Delivery platform, which shows potential for liver-targeted delivery of large molecules Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2023. The company's management will host a webcast and conference call on Monday, November 13, 2023, after the close of financial markets at 4:30 PM Eastern time / 1:30 PM Pacific time. The live call may be accessed by dialing 1-877-423-9813 (domestic) or 1-201-689-8573 (international) and entering the conference code: 13741259. A live webcast will be available via the Investor Relations section of the company website, wit
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced achievement of its device performance targets for the company's BioJet™ platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. The company announced during its recent quarterly conference call that it had preliminary results from animal testing indicating achievement of both its device function targets and its performance target of greater than or equal to 15% average bioavailability with the autonomous ve
SAN DIEGO, July 17, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report financial results and provide a corporate update for the second quarter ended June 30, 2023. The company's management will host a webcast and conference call on Monday, August 14, 2023, after the close of financial markets at 4:30 PM Eastern time / 1:30 PM Pacific time. The live call may be accessed by dialing 1-877-423-9813 (domestic) or 1-201-689-8573 (international) and entering the conference code: 13740025. A live webcast will be available via the Investor Relations section of the company website, with a
HC Wainwright & Co. analyst Joseph Pantginis reiterates Biora Therapeutics (NASDAQ:BIOR) with a Buy and maintains $15 price target.
Drug-device combination leverages Biora's NaviCap™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform's ability to deliver therapeutics directly to the colonDrug absorption in colonic tissue extended to distal colon, suggesting pan-colonic deliveryCompany to host virtual event with key opinion leaders on July 17
Gainers ASLAN Pharma (NASDAQ:ASLN) shares moved upwards by 11.9% to $0.4 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Biora Therapeutics (NASDAQ:BIOR) shares rose 11.64% to $0.75. The company's market cap stands at $26.9 million. Qualigen Therapeutics (NASDAQ:QLGN) shares increased by 10.99% to $0.19. The market value of their outstanding shares is at $1.2 million. CVRx (NASDAQ:CVRX) stock moved upwards by 9.48% to $12.0. The company's market cap stands at $259.1 million. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock increased by 8.68% to $0.27. Fresh2 Group (NASDAQ:FRES) shares rose 7.56% to $0.34. The market value
-SEC Filing
-SEC Filing
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit, which will take place June 18–20, 2024 in Boston. Details of the presentation are as follows:BPresentation Title:Empowering Peptide Self Administration with Needle-Free Smart CapsulesTrack: Pioneering Devices to Increase the Reach of Peptide APIsDate & Time:Wednesday, June 19, 2024 from 2:15 to 2:45 PM Eastern timePresenting Author:Sharat Singh, PhD, Head of Research, Biora Therapeutics, Inc.Dr. Singh will also participate in a panel di
Shares of NetEase, Inc. (NASDAQ:NTES) fell during Friday's session after the company reported worse-than-expected first-quarter revenue. NetEase reported fiscal first-quarter 2024 revenue growth of 7.2% year-on-year to $3.72 billion (26.9 billion Chinese yuan), missing the analyst consensus estimate of $3.79 billion. The Chinese gaming player’s adjusted EPADS of $1.81 beat the analyst consensus estimate of $1.79, according to data from Benzinga Pro. NetEase shares declined 4% to $91.02 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Akanda Corp. (NASDAQ:AKAN) shares climbed 101% to $4.81. The international medical cannabis company implemented
Shares of Ross Stores, Inc. (NASDAQ:ROST) rose sharply in today's pre-market trading after the company reported better-than-expected earnings for its first quarter and increased its profit forecast for the year. The company posted quarterly revenue of $4.858 billion, versus estimates of $4.833 billion. Earnings came in at $1.46 per share, versus estimates of $1.34 per share, according to data from Benzinga Pro. Ross Stores shares jumped 8.2% to $142.73 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Netcapital Inc. (NASDAQ:NCPL) rose 105.2% to $0.3587 in today's pre-market trading after jumping 15% on Thursday. Akanda Cor
Gainers Cue Health (NASDAQ:HLTH) shares moved upwards by 42.1% to $0.13 during Friday's pre-market session. The company's market cap stands at $21.3 million. Innovative Eyewear (NASDAQ:LUCY) stock rose 24.73% to $0.23. The market value of their outstanding shares is at $4.0 million. SCWorx (NASDAQ:WORX) shares increased by 17.02% to $2.2. The company's market cap stands at $2.6 million. Arcus Biosciences (NYSE:RCUS) stock rose 16.33% to $18.94. The company's market cap stands at $1.7 billion. Biora Therapeutics (NASDAQ:BIOR) stock moved upwards by 15.01% to $0.57. The market value of their outstanding shares is at $20.5 million. Jin Medical International (NASDAQ:ZJYL) shares moved upwa